H-Index
14
Scimago Lab
powered by Scopus
eISSN: 2373-3586
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
MSM

Annals
ISI-Home

Get your full text copy in PDF

Short-Term Effect of Twice-Daily Dosage of Repaglinide in Elderly Patients with Type 2 Diabetes

Daisuke Takarabe, Tetsuro Tsujimoto, Miyako Kishimoto, Mitsuhiko Noda

(Department of Endocrinology and Metabolism, Tama-Hokubu Medical Center, Tokyo, Japan)

Med Sci Case Rep 2015; 2:53-57

DOI: 10.12659/MSCR.895993


BACKGROUND: Repaglinide is typically administered 3 times daily before meals. However, treatment regimens for elderly patients should be simplified as much as possible.
CASE REPORT: We report the cases of 2 elderly patients with type 2 diabetes (T2D) admitted to the hospital for glycemic control. Using continuous glucose monitoring, we monitored the effects of a twice-daily dosage of repaglinide compared with 3-times-daily dosage in the patients. In patient 1, we observed some worsening of glycemic control during the twice-daily treatment period, compared with the effects during the 3-times-daily treatment period. However, in patient 2, we did not observe any apparent worsening of that.
CONCLUSIONS: In some patients, the twice-daily dosage of repaglinide may be useful for their glycemic control to reach target.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree